Safety of Catheter Ablation Therapy for Atrial Fibrillation in Cardiac Amyloidosis

Background Despite the high burden of atrial fibrillation in cardiac amyloidosis (CA), the safety of catheter ablation therapy in CA is not well established. We sought to examine short‐term safety outcomes following atrial fibrillation ablation in patients with CA compared with matched patients with dilated cardiomyopathy (DCM). Methods and Results Using data from the National Inpatient Sample, we identified all hospitalizations for atrial fibrillation ablation from the fourth quarter of 2015 through 2019. Admissions for CA and DCM were matched in a 1: 5 ratio using propensity scores based on the following sociodemographics: age, sex, race or ethnicity, payor, median income, comorbidities, and hospital characteristics. We compared in‐hospital outcomes between both cardiomyopathies. We identified 1395 unweighted hospitalizations (representing 6750 national hospitalizations) for atrial fibrillation ablation, out of which 45 (3. 2%) were admissions for CA. Compared with DCM, patients with CA were older (72. 9 versus 65. 1 years), had a higher burden of prior stroke (20. 0% versus 8. 6%) and chronic kidney disease (53. 3% versus 33. 6%), and were less likely to have a prior implantable cardioverter‐defibrillator (4. 4% versus 23. 0%). We successfully matched 42 CAs to 210 DCM hospitalizations. After matching, there was no difference in total complications (14. 3% versus 10. 5%, P =0. 60), length‐of‐stay (3. 1 versus 2. 1 days, P =0. 23), home disposition (97. 6% versus 96. 2%, P =0. 65), and total charges (137 250 versus 133 910, P =0. 24). Conclusions In this nationally representative study of atrial fibrillation catheter ablation in CA, short‐term safety outcomes and complication rates were similar to a propensity score‐matched cohort of DCM. Further studies exploring long‐term safety outcomes are needed.